These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26606967)

  • 21. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
    Montero JC; García-Alonso S; Ocaña A; Pandiella A
    Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
    Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
    J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
    Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
    Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
    Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
    Uppal H; Doudement E; Mahapatra K; Darbonne WC; Bumbaca D; Shen BQ; Du X; Saad O; Bowles K; Olsen S; Lewis Phillips GD; Hartley D; Sliwkowski MX; Girish S; Dambach D; Ramakrishnan V
    Clin Cancer Res; 2015 Jan; 21(1):123-33. PubMed ID: 25370470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
    Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
    Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT; Li G; Parsons K; Phillips GL; Sliwkowski MX
    Breast Cancer Res Treat; 2011 Jul; 128(2):347-56. PubMed ID: 20730488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
    Bourdeanu L; Luu T
    Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
    Lianos GD; Roukos DH
    Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597
    [No Abstract]   [Full Text] [Related]  

  • 36. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.
    Burris HA; Tibbitts J; Holden SN; Sliwkowski MX; Lewis Phillips GD
    Clin Breast Cancer; 2011 Oct; 11(5):275-82. PubMed ID: 21729661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
    Iwata TN; Sugihara K; Wada T; Agatsuma T
    PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?
    Sendur MA; Aksoy S; Ozdemir Y; Zengin N; Altundag K
    J BUON; 2013; 18(3):801. PubMed ID: 24065505
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.